Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Kanaph Therapeutics Inc. manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are split between 2 distinct art units and 2 distinct examiners, reflecting a diverse set of biological or pharmaceutical claims. This distribution ensures that the company's 2 pending actions are not concentrated under a single official, which can help mitigate the impact of any single examiner's specific procedural preferences.
The busiest examiner, AEDER, SEAN E, is responsible for 1 pending office action. Since there are 2 pending actions in total, the workload is shared equally with the other of the 2 distinct examiners. Practitioners must manage prosecution strategies across 2 distinct art units to address the specific requirements of each pending matter. This decentralized approach requires careful coordination to ensure that the arguments presented to the 2 distinct art units remain consistent with the company's broader intellectual property goals in the biotechnology sector.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AEDER, SEAN E | 1 | 56.9% | +20.0% |
| OUSPENSKI, ILIA I | 1 | 77.3% | +20.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18041392 | FUSION PROTEIN COMPRISING IL-12 AND ANTI-FAP ANTIBODY, AND USE THEREOF | AEDER, SEAN E | 28d |
| 18004613 | FUSION PROTEIN INCLUDING COMPLEMENT PATHWAY INHIBITOR AND ANGIOGENESIS INHIBITOR AND USE THEREOF | OUSPENSKI, ILIA I | 76d |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18041392 | FUSION PROTEIN COMPRISING IL-12 AND ANTI-FAP ANTIBODY, AND USE THEREOF | AEDER, SEAN E | 1642 | §103 | Final Rejection | 28d | Pending | Feb 10, 2023 |
| 18004613 | FUSION PROTEIN INCLUDING COMPLEMENT PATHWAY INHIBITOR AND ANGIOGENESIS INHIBITOR AND USE THEREOF | OUSPENSKI, ILIA I | 1644 | §112 | Final Rejection | 76d | Pending | Jan 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKanaph Therapeutics Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Sean E Aeder has the most, with 1 of Kanaph Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
